IP Library Granted Patent US 10,030,230
Granted Patent B2
US 10,030,230 · App. 15/369,776 · Granted Jul 24, 2018

Personalized production of biologics and method for reprogramming somatic cells

Inventor: Theresa A. Deisher (Seattle, WA)
C12N5/0696A61K35/545A61K38/00A61K39/00C07K14/00C07K16/00C07K2317/14C07K2317/41C12N2510/02C12N2517/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,030,230
App. No.
15/369,776
Granted
Jul 24, 2018
Kind
B2
Abstract

Use invention provides a method for producing polypeptide protein products and nucleic acid products having reduced levels of antigenicity in an animal being treated with a biologic product. Somatic cells are isolated from an animal, transformed into pluripotent stem cells, transfected with a nucleic acid(s) of interest, and re-differentiated towards somatic cells known to be high level producers of the desired nucleic acid product. The invention can be used to derive a general cell line to treat populations, racial specific cell lines to treat ethnic groups, or patient specific cell lines to treat individuals. Additionally, the invention provides a method to allow induced pluripotent stem cells to be re-differentiated towards their somatic cell of origin so that the cells can be used to therapeutically treat an animal without resulting teratoma formation.

Claims (6)

1. A method for producing an isolated nucleic acid or virus comprising transfecting a synthetically-produced Pluripotent Stem Cell (spPSC) with a vector that encodes and produces said nucleic acid or virus when transfected into said spPSC, under conditions wherein said nucleic acid or virus is produced and isolated from said spPSC, and wherein the spPSC is produced from a cell of an animal.

2. The method of claim 1 further comprising immortalizing the transfected spPSC.

3. The method of claim 2 further comprising inducing differentiation of the transfected, immortalized spPSCs.

4. The method of claim 1 further comprising inducing differentiation of the transfected spPSCs.

5. The method of claim 4 further comprising immortalizing the transfected, differentiated cells.

6. The method of claim 1 wherein the spPSC is selected from the group consisting of: transfected non-Pluripotent Stem Cells, pluripotent stem cells produced by Somatic cell nuclear transfer (SCNT pluripotent stem cells), pluripotent stem cells produced by Altered nuclear transfer, oocyte assisted reprogramming (ANT-OAR pluripotent stem cells) and pluripotent stem cells produced by parthenogenesis (PGA pluripotent).

Assignments (3)
CHANGE OF NAME Recorded Nov 7, 2017
From: AVE MARIA BIOTECHNOLOGY, LLC
To: AVM BIOTECHNOLOGY, LLC
Reel/Frame 044393/0389 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED ON REEL 040604 FRAME 0428. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 7, 2017
From: DEISHER, THERESA A.
To: AVE MARIA BIOTECHNOLOGY LLC
Reel/Frame 045013/0852 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2016
From: DEISHER, THERESA
To: AVM BIOTECHNOLOGY, LLC
Reel/Frame 040604/0428 →
Continuity (4)
Continuation 13342704 · Jan 3, 2012
Provisional Application 61429409 · Jan 3, 2011
Provisional Application 61431376 · Jan 10, 2011
Related Publication 20170081641A1 · Mar 23, 2017
Cited By (2)
US 12,648,952 US 12,653,891